{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:52:07Z","timestamp":1790607127481,"version":"4.1.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), continues to challenge treatment paradigms. Advancements in therapeutic options have been have been driven by Phase 2 and 3 clinical trials of new drug classes, particularly sphingosine-1-phosphate (S1P) modulators and interleukin-23 (IL-23) inhibitors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This review synthesizes findings from Phase 2 and 3 clinical trials conducted up to early 2024, focusing on the impact of S1P modulators and IL-23 inhibitors on IBD management. Drugs such as ozanimod, etrasimod, risankizumab, mirikizumab, guselkumab, and brasikumab were evaluated for their efficacy and safety profiles.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>S1P modulators, such as ozanimod and etrasimod, effectively regulate immune cell trafficking to reduce inflammation and several trials highlight their clinical effectiveness in both inducing and maintaining remission in IBD, highlighting its long-term safety and sustained therapeutic effects. Additionally, IL-23 inhibitors including risankizumab, mirikizumab, and guselkumab, which disrupt key inflammatory cytokine pathways, have already shown significant effectiveness in inducing and maintaining remission in both CD and UC, with favorable safety profiles across multiple studies, suggesting their potential as critical components in managing IBD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The clinical trials indicate that both S1P modulators and IL-23 inhibitors offer promising therapeutic benefits and maintain strong safety profiles, positioning them as potential cornerstone treatments for IBD. Despite these advancements, further exploration into long-term safety and the development of personalized treatment strategies is essential for maximizing clinical outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00535-024-02130-x","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T12:01:35Z","timestamp":1720526495000},"page":"761-787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment\u2014insights from Phase II and III trials"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-8192","authenticated-orcid":false,"given":"Sara","family":"Massironi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Furfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bencardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Allocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"2130_CR1","unstructured":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020;5:17\u201330."},{"issue":"3","key":"2130_CR2","first-page":"1","volume":"20","author":"F D'Amico","year":"2023","unstructured":"D\u2019Amico F, Fasulo E, Jairath V, et al. Management and treatment optimization of patients with mild to moderate ulcerative colitis. Expert Rev Clin Immunol. 2023;20(3):1\u201314.","journal-title":"Expert Rev Clin Immunol"},{"key":"2130_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S2468-1253(21)00065-0","volume":"6","author":"D Alsoud","year":"2021","unstructured":"Alsoud D, Verstockt B, Fiocchi C, et al. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021;6:589\u201395.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2130_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11123229","author":"M Vebr","year":"2023","unstructured":"Vebr M, Pomaha\u010dov\u00e1 R, S\u00fdkora J, et al. A narrative review of cytokine networks: pathophysiological and therapeutic implications for inflammatory bowel disease pathogenesis. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11123229.","journal-title":"Biomedicines"},{"key":"2130_CR5","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/ueg2.12442","volume":"11","author":"L Calm\u00e9jane","year":"2023","unstructured":"Calm\u00e9jane L, Laharie D, Kirchgesner J, et al. Review article: updated management of acute severe ulcerative colitis: from steroids to novel medical strategies. United European Gastroenterol J. 2023;11:722\u201332.","journal-title":"United European Gastroenterol J"},{"key":"2130_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/apt.17622","volume":"58","author":"A Dignass","year":"2023","unstructured":"Dignass A, Rath S, Kleindienst T, et al. Review article: translating STRIDE-II into clinical reality\u2014opportunities and challenges. Aliment Pharmacol Ther. 2023;58:492\u2013502.","journal-title":"Aliment Pharmacol Ther"},{"key":"2130_CR7","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570\u201383.","journal-title":"Gastroenterology"},{"key":"2130_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030747","author":"Y Zurba","year":"2023","unstructured":"Zurba Y, Gros B, Shehab M. Exploring the pipeline of novel therapies for inflammatory bowel disease; state of the art review. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11030747.","journal-title":"Biomedicines"},{"key":"2130_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11894-021-00829-y","volume":"23","author":"L Sattler","year":"2021","unstructured":"Sattler L, Hanauer SB, Malter L. Immunomodulatory agents for treatment of patients with inflammatory bowel disease (review safety of anti-TNF, anti-integrin, anti IL-12\/23, JAK inhibition, sphingosine 1-phosphate receptor modulator, azathioprine \/ 6-MP and methotrexate). Curr Gastroenterol Rep. 2021;23:30.","journal-title":"Curr Gastroenterol Rep"},{"key":"2130_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.coph.2020.10.015","volume":"55","author":"F D'Amico","year":"2020","unstructured":"D\u2019Amico F, Peyrin-Biroulet L, Danese S, et al. New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming? Curr Opin Pharmacol. 2020;55:141\u201350.","journal-title":"Curr Opin Pharmacol"},{"key":"2130_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/ecco-jcc\/jjx117","volume":"12","author":"P Hindryckx","year":"2018","unstructured":"Hindryckx P, Vande Casteele N, Novak G, et al. The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug[s] for Our patients? J Crohns Colitis. 2018;12:105\u201319.","journal-title":"J Crohns Colitis"},{"key":"2130_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/ueg2.12366","volume":"11","author":"F Magro","year":"2023","unstructured":"Magro F, Moreira PL, Catalano G, et al. Has the therapeutical ceiling been reached in Crohn\u2019s disease randomized controlled trials? a systematic review and meta-analysis. United European Gastroenterol J. 2023;11:202\u201317.","journal-title":"United European Gastroenterol J"},{"key":"2130_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17961","author":"S Akiyama","year":"2024","unstructured":"Akiyama S, Yokoyama K, Yagi S, et al. Efficacy and safety of filgotinib for ulcerative colitis: a real-world multicenter retrospective study in Japan. Aliment Pharmacol Ther. 2024. https:\/\/doi.org\/10.1111\/apt.17961.","journal-title":"Aliment Pharmacol Ther"},{"key":"2130_CR14","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/gutjnl-2011-300904","volume":"61","author":"S Danese","year":"2012","unstructured":"Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut. 2012;61:918\u201332.","journal-title":"Gut"},{"key":"2130_CR15","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","volume":"6","author":"S Singh","year":"2021","unstructured":"Singh S, Murad MH, Fumery M, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn\u2019s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:1002\u201314.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2130_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.bpg.2018.05.005","volume":"32\u201333","author":"S Bonovas","year":"2018","unstructured":"Bonovas S, Pantavou K, Evripidou D, et al. Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses. Best Pract Res Clin Gastroenterol. 2018;32\u201333:43\u20137.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2130_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010224","author":"J Fanizza","year":"2023","unstructured":"Fanizza J, D\u2019Amico F, Lusetti F, et al. The role of IL-23 inhibitors in Crohn\u2019s disease. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm13010224.","journal-title":"J Clin Med"},{"key":"2130_CR18","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1080\/17474124.2023.2295496","volume":"17","author":"AM Johnson","year":"2023","unstructured":"Johnson AM, Loftus EV Jr. Risankizumab to treat moderately to severely active Crohn\u2019s disease in adults: an evaluation of trials and data. Expert Rev Gastroenterol Hepatol. 2023;17:1169\u201383.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2130_CR19","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1007\/s10620-023-08014-z","volume":"68","author":"SK Vuyyuru","year":"2023","unstructured":"Vuyyuru SK, Solitano V, Hogan M, et al. Efficacy and safety of IL-12\/23 and IL-23 inhibitors for Crohn\u2019s disease: systematic review and meta-analysis. Dig Dis Sci. 2023;68:3702\u201313.","journal-title":"Dig Dis Sci"},{"key":"2130_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/apt.17816","volume":"59","author":"R Panaccione","year":"2024","unstructured":"Panaccione R, Danese S, Zhou W, et al. Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2024;59:393\u2013408.","journal-title":"Aliment Pharmacol Ther"},{"key":"2130_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1053\/j.gastro.2023.09.011","volume":"166","author":"R Khanna","year":"2024","unstructured":"Khanna R. Upadacitinib for the treatment of Crohn\u2019s disease. Gastroenterology. 2024;166:211.","journal-title":"Gastroenterology"},{"key":"2130_CR22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/ecco-jcc\/jjad153","volume":"18","author":"A Singh","year":"2024","unstructured":"Singh A, Midha V, Kaur K, et al. Tofacitinib versus oral prednisolone for induction of remission in moderately active ulcerative colitis [ORCHID]: a prospective, open-label, randomized. Pilot Study J Crohns Colitis. 2024;18:300\u20137.","journal-title":"Pilot Study J Crohns Colitis"},{"key":"2130_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/14728214.2023.2186399","volume":"28","author":"L Neurath","year":"2023","unstructured":"Neurath L, D\u2019Amico F, Danese S. Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials. Expert Opin Emerg Drugs. 2023;28:27\u201342.","journal-title":"Expert Opin Emerg Drugs"},{"key":"2130_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01008-6","author":"MF Neurath","year":"2024","unstructured":"Neurath MF. Strategies for targeting cytokines in inflammatory bowel disease. Nat Rev Immunol. 2024. https:\/\/doi.org\/10.1038\/s41577-024-01008-6.","journal-title":"Nat Rev Immunol"},{"key":"2130_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/14728214.2024.2303116","volume":"29","author":"P Wetwittayakhlang","year":"2024","unstructured":"Wetwittayakhlang P, Bessissow T, Lakatos PL. Novel and emerging drugs for the treatment of Crohn\u2019s disease: a review of phase II and III trials. Expert Opin Emerg Drugs. 2024;29:19\u201334.","journal-title":"Expert Opin Emerg Drugs"},{"key":"2130_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12155014","author":"S Bencardino","year":"2023","unstructured":"Bencardino S, D\u2019Amico F, Faggiani I, et al. Efficacy and safety of S1P1 receptor modulator drugs for patients with moderate-to-severe ulcerative colitis. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12155014.","journal-title":"J Clin Med"},{"key":"2130_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3748\/wjg.v29.i1.110","volume":"29","author":"E Tourkochristou","year":"2023","unstructured":"Tourkochristou E, Mouzaki A, Triantos C. Unveiling the biological role of sphingosine-1-phosphate receptor modulators in inflammatory bowel diseases. World J Gastroenterol. 2023;29:110\u201325.","journal-title":"World J Gastroenterol"},{"key":"2130_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071735","author":"A Dal Buono","year":"2022","unstructured":"Dal Buono A, Gabbiadini R, Alfarone L, et al. Sphingosine 1-phosphate modulation in inflammatory bowel diseases: keeping lymphocytes out of the intestine. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10071735.","journal-title":"Biomedicines"},{"key":"2130_CR29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41575-021-00574-7","volume":"19","author":"B Verstockt","year":"2022","unstructured":"Verstockt B, Vetrano S, Salas A, et al. Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2022;19:351\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2130_CR30","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/17474124.2020.1785868","volume":"14","author":"D Gilardi","year":"2020","unstructured":"Gilardi D, Gabbiadini R, Allocca M, et al. PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. Expert Rev Gastroenterol Hepatol. 2020;14:797\u2013806.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2130_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/14712598.2020.1732919","volume":"20","author":"M Argollo","year":"2020","unstructured":"Argollo M, Furfaro F, Gilardi D, et al. Modulation of sphingosine-1-phosphate in ulcerative colitis. Expert Opin Biol Ther. 2020;20:413\u201320.","journal-title":"Expert Opin Biol Ther"},{"key":"2130_CR32","doi-asserted-by":"publisher","first-page":"1191782","DOI":"10.3389\/fimmu.2023.1191782","volume":"14","author":"V Navarro-Comp\u00e1n","year":"2023","unstructured":"Navarro-Comp\u00e1n V, Puig L, Vidal S, et al. The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases. Front Immunol. 2023;14:1191782.","journal-title":"Front Immunol"},{"key":"2130_CR33","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s40265-023-01882-9","volume":"83","author":"SK Vuyyuru","year":"2023","unstructured":"Vuyyuru SK, Shackelton LM, Hanzel J, et al. Targeting IL-23 for IBD: rationale and progress to date. Drugs. 2023;83:873\u201391.","journal-title":"Drugs"},{"key":"2130_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac034","author":"GW Sewell","year":"2022","unstructured":"Sewell GW, Kaser A. Interleukin-23 in the Pathogenesis of Inflammatory Bowel Disease and Implications for Therapeutic Intervention. J Crohns Colitis. 2022. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac034.","journal-title":"J Crohns Colitis"},{"key":"2130_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab185","author":"TL Parigi","year":"2022","unstructured":"Parigi TL, Iacucci M, Ghosh S. Blockade of IL-23: what is in the Pipeline? J Crohns Colitis. 2022. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab185.","journal-title":"J Crohns Colitis"},{"key":"2130_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac038","author":"BD McDonald","year":"2022","unstructured":"McDonald BD, Dyer EC, Rubin DT. IL-23 Monoclonal antibodies for IBD: so many, so different? J Crohns Colitis. 2022. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac038.","journal-title":"J Crohns Colitis"},{"key":"2130_CR37","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1093\/ibd\/izab135","volume":"27","author":"S Danese","year":"2021","unstructured":"Danese S, Peyrin-Biroulet L. Selective tyrosine kinase 2 inhibition for treatment of inflammatory bowel disease: new hope on the rise. Inflamm Bowel Dis. 2021;27:2023\u201330.","journal-title":"Inflamm Bowel Dis"},{"key":"2130_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.665968","volume":"12","author":"E Tourkochristou","year":"2021","unstructured":"Tourkochristou E, Triantos C, Mouzaki A. The influence of nutritional factors on immunological outcomes. Front Immunol. 2021;12: 665968.","journal-title":"Front Immunol"},{"key":"2130_CR39","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.2147\/JIR.S353038","volume":"15","author":"Q Lu","year":"2022","unstructured":"Lu Q, Yang MF, Liang YJ, et al. Immunology of inflammatory bowel disease: molecular mechanisms and therapeutics. J Inflamm Res. 2022;15:1825\u201344.","journal-title":"J Inflamm Res"},{"key":"2130_CR40","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/s41590-019-0415-0","volume":"20","author":"MF Neurath","year":"2019","unstructured":"Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol. 2019;20:970\u20139.","journal-title":"Nat Immunol"},{"key":"2130_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","volume":"13","author":"HS de Souza","year":"2016","unstructured":"de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13\u201327.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2130_CR42","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.autrev.2017.02.013","volume":"16","author":"JH Park","year":"2017","unstructured":"Park JH, Peyrin-Biroulet L, Eisenhut M, et al. IBD immunopathogenesis: a comprehensive review of inflammatory molecules. Autoimmun Rev. 2017;16:416\u201326.","journal-title":"Autoimmun Rev"},{"key":"2130_CR43","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1158\/1940-6207.CAPR-16-0124","volume":"9","author":"PS Dulai","year":"2016","unstructured":"Dulai PS, Sandborn WJ, Gupta S. Colorectal cancer and dysplasia in inflammatory bowel disease: a review of disease epidemiology, pathophysiology, and management. Cancer Prev Res (Phila). 2016;9:887\u201394.","journal-title":"Cancer Prev Res (Phila)"},{"key":"2130_CR44","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","volume":"16","author":"L Peyrin-Biroulet","year":"2017","unstructured":"Peyrin-Biroulet L, Christopher R, Behan D, et al. Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmun Rev. 2017;16:495\u2013503.","journal-title":"Autoimmun Rev"},{"key":"2130_CR45","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1124\/pr.107.07113","volume":"60","author":"K Takabe","year":"2008","unstructured":"Takabe K, Paugh SW, Milstien S, et al. \u201cInside-out\u201d signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008;60:181\u201395.","journal-title":"Pharmacol Rev"},{"key":"2130_CR46","doi-asserted-by":"publisher","first-page":"S678","DOI":"10.1093\/ecco-jcc\/jjx107","volume":"12","author":"S Danese","year":"2018","unstructured":"Danese S, Furfaro F, Vetrano S. Targeting S1P in inflammatory bowel disease: new avenues for modulating intestinal leukocyte migration. J Crohns Colitis. 2018;12:S678-s686.","journal-title":"J Crohns Colitis"},{"key":"2130_CR47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/17474124.2020.1709446","volume":"14","author":"TL Parigi","year":"2020","unstructured":"Parigi TL, Roda G, Argollo M, et al. Is there a role for therapeutic sphingolipids in inflammatory bowel disease? Expert Rev Gastroenterol Hepatol. 2020;14:47\u201354.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2130_CR48","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/bph.13476","volume":"173","author":"FL Scott","year":"2016","unstructured":"Scott FL, Clemons B, Brooks J, et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. Br J Pharmacol. 2016;173:1778\u201392.","journal-title":"Br J Pharmacol"},{"key":"2130_CR49","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1212\/WNL.0b013e31820d5ec1","volume":"76","author":"T Hla","year":"2011","unstructured":"Hla T, Brinkmann V. Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation. Neurology. 2011;76:S3-8.","journal-title":"Neurology"},{"key":"2130_CR50","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1177\/13524585221102584","volume":"28","author":"BA Cree","year":"2022","unstructured":"Cree BA, Selmaj KW, Steinman L, et al. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial. Mult Scler. 2022;28:1944\u201362.","journal-title":"Mult Scler"},{"key":"2130_CR51","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/apt.16741","volume":"55","author":"J Wang","year":"2022","unstructured":"Wang J, Goren I, Yang B, et al. Review article: the sphingosine 1 phosphate\/sphingosine 1 phosphate receptor axis\u2014a unique therapeutic target in inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55:277\u201391.","journal-title":"Aliment Pharmacol Ther"},{"key":"2130_CR52","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/jcph.887","volume":"57","author":"JQ Tran","year":"2017","unstructured":"Tran JQ, Hartung JP, Peach RJ, et al. Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator. J Clin Pharmacol. 2017;57:988\u201396.","journal-title":"J Clin Pharmacol"},{"key":"2130_CR53","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","volume":"374","author":"WJ Sandborn","year":"2016","unstructured":"Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374:1754\u201362.","journal-title":"N Engl J Med"},{"key":"2130_CR54","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","volume":"385","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Feagan BG, D\u2019Haens G, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385:1280\u201391.","journal-title":"N Engl J Med"},{"key":"2130_CR55","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","volume":"15","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Feagan BG, Hanauer S, et al. Long-term efficacy and safety of ozanimod in moderately to severely active ulcerative colitis: results from the open-label extension of the randomized, phase 2 TOUCHSTONE study. J Crohns Colitis. 2021;15:1120\u20139.","journal-title":"J Crohns Colitis"},{"key":"2130_CR56","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.14309\/01.ajg.0000722920.48091.e7","volume":"115","author":"S William","year":"2020","unstructured":"William S, Brian F, Stephen H, et al. P031 Ozanimod in patients with moderate-to-severe ulcerative colitis: long-term safety and efficacy from the phase 2 TOUCHSTONE study 4-year open-label extension. Am J Gastroenterol. 2020;115:S8.","journal-title":"Am J Gastroenterol"},{"key":"2130_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad146","author":"S Danese","year":"2023","unstructured":"Danese S, Panaccione R, Abreu MT, et al. Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the true North open-label extension. J Crohns Colitis. 2023. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad146.","journal-title":"J Crohns Colitis"},{"key":"2130_CR58","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","volume":"5","author":"BG Feagan","year":"2020","unstructured":"Feagan BG, Sandborn WJ, Danese S, et al. Ozanimod induction therapy for patients with moderate to severe Crohn\u2019s disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol. 2020;5:819\u201328.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2130_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106958","volume":"122","author":"BG Feagan","year":"2022","unstructured":"Feagan BG, Schreiber S, Afzali A, et al. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn\u2019s disease: the YELLOWSTONE clinical trial program. Contemp Clin Trials. 2022;122: 106958.","journal-title":"Contemp Clin Trials"},{"key":"2130_CR60","doi-asserted-by":"publisher","first-page":"187","DOI":"10.58347\/tml.2023.1690b","volume":"65","author":"A Papapetropoulos","year":"2023","unstructured":"Papapetropoulos A, Topouzis S, Alexander SP, Cortese-Krott M, Kendall DA, Martemyanov KA, Mauro C, Nagercoil N, Panettieri RA, Patel HH, Schulz R. Etrasimod (Velsipity) for ulcerative colitis. Med Lett Drugs Ther. 2023;65:187\u20139.","journal-title":"Med Lett Drugs Ther"},{"key":"2130_CR61","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/imt-2022-0255","volume":"15","author":"P Wils","year":"2023","unstructured":"Wils P, Peyrin-Biroulet L. Etrasimod for the treatment of ulcerative colitis. Immunotherapy. 2023;15:311\u201321.","journal-title":"Immunotherapy"},{"key":"2130_CR62","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety of Etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158:550\u201361.","journal-title":"Gastroenterology"},{"key":"2130_CR63","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","volume":"15","author":"S Vermeire","year":"2021","unstructured":"Vermeire S, Chiorean M, Pan\u00e9s J, et al. Long-term safety and efficacy of Etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study. J Crohns Colitis. 2021;15:950\u20139.","journal-title":"J Crohns Colitis"},{"key":"2130_CR64","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae038","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Dubinsky MC, Sands BE, et al. Efficacy and safety of Etrasimod in patients with moderately to severely active isolated proctitis: results from the phase 3 ELEVATE UC clinical programme. J Crohns Colitis. 2024. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae038.","journal-title":"J Crohns Colitis"},{"key":"2130_CR65","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401:1159\u201371.","journal-title":"Lancet"},{"key":"2130_CR66","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/ecco-jcc\/jjab201","volume":"16","author":"G D'Haens","year":"2022","unstructured":"D\u2019Haens G, Danese S, Davies M, et al. A phase II, multicentre, randomised, double-blind, placebo-controlled study to evaluate safety, tolerability, and efficacy of Amiselimod in patients with moderate to severe active Crohn\u2019s disease. J Crohns Colitis. 2022;16:746\u201356.","journal-title":"J Crohns Colitis"},{"key":"2130_CR67","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.1135245","volume":"314","author":"RH Duerr","year":"2006","unstructured":"Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461\u20133.","journal-title":"Science"},{"key":"2130_CR68","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","volume":"20","author":"B Verstockt","year":"2023","unstructured":"Verstockt B, Salas A, Sands BE, et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2023;20:433\u201346.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2130_CR69","doi-asserted-by":"publisher","first-page":"5823","DOI":"10.3748\/wjg.v21.i19.5823","volume":"21","author":"CS C\u0103tan\u0103","year":"2015","unstructured":"C\u0103tan\u0103 CS, Berindan Neagoe I, Cozma V, et al. Contribution of the IL-17\/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2015;21:5823\u201330.","journal-title":"World J Gastroenterol"},{"key":"2130_CR70","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac011","author":"F D'Amico","year":"2022","unstructured":"D\u2019Amico F, Peyrin-Biroulet L, Danese S. Ustekinumab in Crohn\u2019s disease: new data for positioning in treatment algorithm. J Crohns Colitis. 2022. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac011.","journal-title":"J Crohns Colitis"},{"key":"2130_CR71","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13706","volume":"17","author":"Y Pang","year":"2024","unstructured":"Pang Y, D\u2019Cunha R, Winzenborg I, et al. Risankizumab: mechanism of action, clinical and translational science. Clin Transl Sci. 2024;17: e13706.","journal-title":"Clin Transl Sci"},{"key":"2130_CR72","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0219","author":"F Lusetti","year":"2024","unstructured":"Lusetti F, D\u2019Amico F, Allocca M, et al. Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn\u2019s disease. Immunotherapy. 2024. https:\/\/doi.org\/10.2217\/imt-2023-0219.","journal-title":"Immunotherapy"},{"key":"2130_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12547","author":"B Caron","year":"2024","unstructured":"Caron B, Habert A, Bonsack O, et al. Difficult-to-treat inflammatory bowel disease: effectiveness and safety of 4th and 5th lines of treatment. United European Gastroenterol J. 2024. https:\/\/doi.org\/10.1002\/ueg2.12547.","journal-title":"United European Gastroenterol J"},{"key":"2130_CR74","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad315","author":"D Alsoud","year":"2024","unstructured":"Alsoud D, Sabino J, Franchimont D, et al. Real-world effectiveness and safety of Risankizumab in patients with moderate to severe Multirefractory Crohn\u2019s disease: a Belgian multicentric Cohort study. Inflamm Bowel Dis. 2024. https:\/\/doi.org\/10.1093\/ibd\/izad315.","journal-title":"Inflamm Bowel Dis"},{"key":"2130_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.11.033","author":"A Zinger","year":"2023","unstructured":"Zinger A, Choi D, Choi N, et al. Risankizumab effectiveness and safety in Crohn\u2019s disease: real-world data from a large tertiary center. Clin Gastroenterol Hepatol. 2023. https:\/\/doi.org\/10.1016\/j.cgh.2023.11.033.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12 Suppl 9","key":"2130_CR76","first-page":"9","volume":"19","author":"I Pbo","year":"2023","unstructured":"Pbo I. Risankizumab induction therapy in patients with moderately to severely active ulcerative colitis: efficacy and safety in the randomized phase 3 INSPIRE study. Gastroenterol Hepatol (N Y). 2023;19(12 Suppl 9):9\u201310.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2130_CR77","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/ecco-jcc\/jjad212.0006","volume":"18","author":"E Louis","year":"2024","unstructured":"Louis E, Panaccione R, Parkes G, et al. OP06 Risankizumab maintenance therapy in patients with moderately to severely active ulcerative colitis: efficacy and safety in the randomised phase 3 COMMAND study. J Crohns Colitis. 2024;18:i10\u20132.","journal-title":"J Crohns Colitis"},{"key":"2130_CR78","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/ecco-jcc\/jjad168","volume":"18","author":"M Ferrante","year":"2024","unstructured":"Ferrante M, Irving PM, Abreu MT, et al. Maintenance risankizumab sustains induction response in patients with crohn\u2019s disease in a randomized phase 3 trial. J Crohns Colitis. 2024;18:416\u201323.","journal-title":"J Crohns Colitis"},{"key":"2130_CR79","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad206","author":"JF Colombel","year":"2023","unstructured":"Colombel JF, Schreiber S, D\u2019Haens G, et al. Risankizumab induction therapy achieves early symptom improvements that are associated with future clinical and endoscopic outcomes in Crohn\u2019s disease: post hoc analysis of the ADVANCE, MOTIVATE, and FORTIFY phase 3 studies. J Crohns Colitis. 2023. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad206.","journal-title":"J Crohns Colitis"},{"key":"2130_CR80","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","volume":"399","author":"G D'Haens","year":"2022","unstructured":"D\u2019Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399:2015\u201330.","journal-title":"Lancet"},{"key":"2130_CR81","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","volume":"399","author":"M Ferrante","year":"2022","unstructured":"Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399:2031\u201346.","journal-title":"Lancet"},{"key":"2130_CR82","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/apt.17358","volume":"57","author":"M Fumery","year":"2023","unstructured":"Fumery M, Defrance A, Roblin X, et al. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn\u2019s disease: A GETAID multicentre cohort study. Aliment Pharmacol Ther. 2023;57:426\u201334.","journal-title":"Aliment Pharmacol Ther"},{"key":"2130_CR83","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D'Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388:2444\u201355.","journal-title":"N Engl J Med"},{"key":"2130_CR84","unstructured":"Two-year efficacy and safety of Mirikizumab following 104 weeks of continuous treatment: interim results from the LUCENT-3 open-label extension study (Ulcerative Colitis). Gastroenterol Hepatol (N Y) 2023;19:10\u201311."},{"key":"2130_CR85","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","volume":"162","author":"BE Sands","year":"2022","unstructured":"Sands BE, Peyrin-Biroulet L, Kierkus J, et al. Efficacy and safety of Mirikizumab in a randomized phase 2 study of patients with Crohn\u2019s disease. Gastroenterology. 2022;162:495\u2013508.","journal-title":"Gastroenterology"},{"key":"2130_CR86","doi-asserted-by":"publisher","first-page":"i7","DOI":"10.1093\/ecco-jcc\/jjad212.0005","volume":"18","author":"M Ferrante","year":"2024","unstructured":"Ferrante M, Danese S, Chen M, et al. OP05 primary efficacy and safety of mirikizumab in moderate to severe Crohn\u2019s disease: results of the treat-through VIVID 1 study. J Crohns Colitis. 2024;18:i7\u20139.","journal-title":"J Crohns Colitis"},{"key":"2130_CR87","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","volume":"162","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, D\u2019Haens GR, Reinisch W, et al. Guselkumab for the treatment of Crohn\u2019s disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology. 2022;162:1650-1664.e8.","journal-title":"Gastroenterology"},{"key":"2130_CR88","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","volume":"9","author":"S Danese","year":"2024","unstructured":"Danese S, Panaccione R, Feagan BG, et al. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn\u2019s disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Lancet Gastroenterol Hepatol. 2024;9:133\u201346.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2130_CR89","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","volume":"165","author":"L Peyrin-Biroulet","year":"2023","unstructured":"Peyrin-Biroulet L, Allegretti JR, Rubin DT, et al. Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study. Gastroenterology. 2023;165:1443\u201357.","journal-title":"Gastroenterology"},{"key":"2130_CR90","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","volume":"153","author":"BE Sands","year":"2017","unstructured":"Sands BE, Chen J, Feagan BG, et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn\u2019s disease: a phase 2a study. Gastroenterology. 2017;153:77-86.e6.","journal-title":"Gastroenterology"},{"key":"2130_CR91","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1186\/s12876-023-03078-7","volume":"23","author":"S Danese","year":"2023","unstructured":"Danese S, Beaton A, Duncan EA, et al. Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn\u2019s disease. BMC Gastroenterol. 2023;23:451.","journal-title":"BMC Gastroenterol"},{"key":"2130_CR92","doi-asserted-by":"publisher","first-page":"i90","DOI":"10.1093\/ecco-jcc\/jjad212.0050","volume":"18","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Bossuyt P, Regueiro M, et al. DOP10 Risankizumab versus Ustekinumab for the achievement of endoscopic outcomes in patients with moderate-to-severe Crohn\u2019s disease: results from the phase 3b SEQUENCE trial. J Crohns Colitis. 2024;18:i90\u20131.","journal-title":"J Crohns Colitis"},{"key":"2130_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10020297","author":"B Garcill\u00e1n","year":"2022","unstructured":"Garcill\u00e1n B, Salavert M, Regueiro JR, et al. Response to vaccines in patients with immune-mediated inflammatory diseases: a narrative review. Vaccines. 2022. https:\/\/doi.org\/10.3390\/vaccines10020297.","journal-title":"Vaccines"},{"key":"2130_CR94","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","volume":"8","author":"BG Feagan","year":"2023","unstructured":"Feagan BG, Sands BE, Sandborn WJ, et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023;8:307\u201320.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2130_CR95","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1007\/s12325-023-02546-6","volume":"40","author":"M Dubinsky","year":"2023","unstructured":"Dubinsky M, Ma C, Griffith J, et al. Matching-adjusted indirect comparison between Risankizumab and Ustekinumab for induction and maintenance treatment of moderately to severely active Crohn\u2019s disease. Adv Ther. 2023;40:3896\u2013911.","journal-title":"Adv Ther"},{"key":"2130_CR96","first-page":"251","volume":"19","author":"V Solitano","year":"2023","unstructured":"Solitano V, Ma C, Han\u017eel J, et al. Advanced combination treatment with biologic agents and novel small molecule drugs for inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2023;19:251\u201363.","journal-title":"Gastroenterol Hepatol (N Y)"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02130-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-024-02130-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02130-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T08:48:43Z","timestamp":1724402923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-024-02130-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":96,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2130"],"URL":"https:\/\/doi.org\/10.1007\/s00535-024-02130-x","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"15 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Silvio Danese reports consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB Inc., and Vifor. There are no financial disclosures or conflicts of interest among the other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}